Clinical Trials on Stage IV Small Lymphocytic Lymphoma in Singapore

Total 29 results

National University Hospital, Singapore
National University of Singapore

Unknown

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Non-Hodgkin's Lymphoma | B-Cell Chronic Lymphocytic Leukemia

Singapore
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Novartis Pharmaceuticals

Active, not recruiting

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

Spain, Korea, Republic of, Israel, Japan, Germany, Singapore, Finland
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Recurrent Nasopharyngeal Undifferentiated Carcinoma | Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Stage IV Nasopharyngeal Undifferentiated Carcinoma...

United States, Singapore, China, Japan
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
National University Hospital, Singapore
Tan Tock Seng Hospital

Unknown

Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer

Stage III Non-Small Cell Lung Cancer

Singapore
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Recurrent Lymphoepithelioma of the Nasopharynx | Recurrent Squamous Cell Carcinoma of the Nasopharynx | Stage IV Lymphoepithelioma of the Nasopharynx | Stage IV Squamous Cell Carcinoma of the Nasopharynx

Singapore
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

Poland, Turkey, Denmark, Singapore, Hungary, Hong Kong, Chile, Malaysia, Brazil, Guatemala, China, Taiwan, South Africa, Colombia, United States, Ukraine, Australia, Mexico
ETOP IBCSG Partners Foundation
Roche Pharma AG

Active, not recruiting

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Singapore, Spain, Korea, Republic of, Switzerland, Germany
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
University of Chicago
National Cancer Institute (NCI)

Completed

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | Stage IV Prostate Cancer

Singapore, United States
GlaxoSmithKline

Completed

Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Singapore, Korea, Republic of
Novartis Pharmaceuticals

Completed

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)

Australia, Spain, Singapore, Italy, United States
National Cancer Institute (NCI)

Completed

Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing Carcinoma

United States, Singapore, China
Novartis Pharmaceuticals

Completed

Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia

Leukaemia

Belgium, Austria, Czechia, France, Germany, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Ireland, Italy, Slovakia, Bulgaria, Singapore, Ukraine, Poland
AstraZeneca

Completed

Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia (CREEK)

Chronic Lymphocytic Leukemia

Malaysia, Saudi Arabia, India, Mexico, Brazil, Singapore, Egypt, Taiwan, Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Kuwait, Panama, Turkey, United Arab Emirates
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States, Singapore, Australia
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Nasopharynx | Stage IV Squamous Cell Carcinoma of the Nasopharynx

United States, Singapore, China
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
National Cancer Institute (NCI)
NRG Oncology

Terminated

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditions

United States, Canada, China, Singapore
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more

Clinical Trials on Stage IV Small Lymphocytic Lymphoma in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations